cisplatin / Generic mfg.  >>  Phase 3
Welcome,         Profile    Billing    Logout  

596 Trials

   Remove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
cisplatin / Generic mfg.
CTR20201857: Phase III clinical study of ametinib mesylate or placebo combined with chemotherapy as perioperative treatment for non-small cell lung cancer

Not yet recruiting
3
350
China
Ameile (aumolertinib) - Jiangsu Hansoh Pharma, EQRx, Pemfexy (pemetrexed) - Eagle Pharma, cisplatin - Generic mfg., carboplatin - Generic mfg.
Jiangsu Hansoh Pharmaceutical Group Co., Ltd./Shanghai Hansoh Biomedical Technology Co., Ltd.
Non-small cell lung cancer;Oncology
 
 
ACTRN12609000642280: The effect of Taxotere, Cisplatin and 5-Fluorouracil (TPF) induction chemotherapy on intratumoral hypoxia in advanced head and neck squamous cell cancer

Recruiting
3
25
 
Peter MacCallum Cancer Centre, Sanofi Aventis
advanced head and neck squamous cell cancer
 
 
ACTRN12607000169448: A Phase 3 study comparing the combination of CAELYX and YONDELIS (the study drug) with CAELYX alone in subjects with advanced relapsed ovarian cancer who have previously had platinum based chemotherapy treatment (eg. Carboplatin/Cisplatin)

Recruiting
3
650
 
Johnson & Johnson Pharmaceutical Research & Development, Johnson & Johnson Pharmaceutical Research & Development
Advanced relapsed Ovarian Cancer - to prolong progression free survival
 
 
ACTRN12605000142639: Good Prognosis Germ Cell Trial

Active, not recruiting
3
260
 
Australian and New Zealand Germ Cell Trials Group at NHMRC Clinical Trials Centre, NHMRC, NSW Cancer Council, donation from Apex Foundationand Apex Clubs of Australia
Histologically confirmed germ cell tumour (seminoma or non-seminoma) with measurable disease or raised concentrations of tumor markers in serum.
 
 
ACTRN12613000279729: TROG 12.01 A Randomised Trial of Weekly Cetuximab and Radiation versus Weekly Cisplatin and Radiation in Good Prognosis Locoregionally Advanced HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Recruiting
3
200
 
Trans-Tasman Radiation Oncology Group, National Health and Medical Research Council (NHMRC), Merck Serono Australia
HPV positive Oropharyngeal Squamous Cell Carcinoma (OPSCC)
 
 
ACTRN12613000496718: Phase 3 Accelerated BEP Trial: A randomised phase 3 trial of accelerated versus standard BEP chemotherapy for patients with intermediate and poor-risk metastatic germ cell tumours

Recruiting
3
500
 
University of Sydney, Cancer Australia
Intermediate and poor-risk metastatic germ cell tumours (GCTs)
 
 
ACTRN12618001236280: Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors

Recruiting
3
420
 
Alliance for Clinical Trials in Oncology, Australian and New Zealand Urogenital and Prostate Cancer Trials (ANZUP)
Germ Cell Tumor, Teratoma, Choriocarcinoma, Germinoma, Mixed Germ Cell Tumor, Yolk Sac Tumor, Childhood Teratoma, Malignant Germ Cell Neoplasm, Extragonadal Seminoma, Non-seminomatous Germ Cell Tumor, Seminoma, Cancer
 
 
jRCTs031180202: JCOG1109: A randomized controlled phase III comparing CF versus DCF versus CF-RT as neoadjuvant treatment for locally advanced esophageal cancer

Completed
3
600
Japan
cisplatin - Generic mfg., docetaxel - Generic mfg., 5-fluorouracil - Generic mfg.
stage IB/II/III thoracic esophageal cancer
 
 
ACHILLES , jRCTs031180175: study/TORG1834 (study/TORG1834)

Active, not recruiting
3
106
Japan
Gilotrif (afatinib) - Boehringer Ingelheim, cisplatin - Generic mfg., carboplatin - Generic mfg., pemetrexed - Generic mfg.
Niigata Cancer Center Hospital
Advanced non-small cell lung cancer
 
 
BEAT-SC, jRCT2080224946: Tecentriq_SCLC(1L)_Bev_comb[]

Completed
3
330
Japan
Tecentriq (atezolizumab) - Roche, Avastin (bevacizumab) - Roche
Chugai Pharmaceutical Co., Ltd.
Extensive-stage Small Cell Lung Cancer
 
 
ACTRN12620001199909: DREAM3R: A phase 3 trial of durvalumab with chemotherapy as first line treatment in mesothelioma

Recruiting
3
480
 
University of Sydney, AstraZeneca Pty Ltd
Pleural Mesothelioma (PM)
 
 
jRCTs031210393: JCOG2002: A randomized phase III study of thoracic radiotherapy for extensive stage small cell lung cancer

Recruiting
3
330
Japan
carboplatin - Generic mfg., etoposide oral - Generic mfg., cisplatin - Generic mfg., Tecentriq (atezolizumab) - Roche, Imfinzi (durvalumab) - AstraZeneca
Dokkyo Medical University Hospital, National Cancer Center Japan
Extensive stage small cell lung cancer
 
 
ChiCTR-IPR-14005500: Recombinant Mutated Human TNF in Combination?with Docetaxel and Carboplatin/Cisplatin in Patients with Stage IIIB/IV Non-Small-Cell Lung Cancer: A Randomized, Phase III Study

Completed
3
600
 
docetaxel and platinum ;chemotherapy plus rmhTNF
Clinical Pharmacology Research Base of West China Medical University; The Fourth Military Medical University, New Taihe Biopharmaceutical Co., Ltd., Guangzhou, China
Advanced Lung Cancer
 
 
NCT00698620: Combination Chemotherapy in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

Active, not recruiting
3
900
US
paclitaxel, doxorubicin, doxorubicin hydrochloride, cisplatin, filgrastim, (G-CSF)
University of Medicine and Dentistry New Jersey, Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Cancer
01/08
 
NCT00705029: Alpha-Lipoic Acid in Preventing Peripheral Neuropathy in Patients Receiving Chemotherapy for Cancer

Recruiting
3
244
US
alpha-lipoic acid, placebo
University of Medicine and Dentistry New Jersey, M.D. Anderson Cancer Center, Jarrow Formulas Inc
Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific
01/09
 
2010-023195-22: Randomised controlled open-label trial of TPF induction chemotherapy in the surgical management of locally advanced head and neck cancer(T = taxane, P = cisplatin, F = 5-fluorouracil)

Ongoing
3
50
Europe
Docetaxel, Cisplatin, Fluorouracil, Concentrate for solution for infusion, Docetaxel, Cisplatin, Fluorouracil
University of Liverpool, Aintree University Hospitals NHS Foundation Trust
Head and Neck Squamous Cell Carcinoma, in any of the following sites:- Lip / Oral Cavity- Paranasal / Nasal- Larynx- Hypopharynx- Cervical Osephagus- Oropharynx (HPV - ve)
 
 
ChiCTR-TRC-09000487: A randomized multicentre control trial of stage III non-small cell lung cancer application of concomitant radiochemotherapy

Completed
3
240
 
to receive concomitant radiochemotherapy with pemetrexed + cisplatin: pemetrexed 500mg/m2, i.v. drip d1; cisplatin 25mg/m2, i.v. drip d1-3. Radiotherapy carried out in the 1st and 4th week. ;to receive concomitant radiochemotherapy with vinorelbine and cisplatin: Vinorelbine 25mg/m2, i.v. drip d1, 8; cisplatin 25mg/m2, i.v. drip d1-3. Radiotherapy carried out in the 1st and 4th week.
Shandong Cancer Hospital; Jiangsu Hansen Pharmaceutical Co. Ltd, Shandong Provincial Scientific and Technological Project
Non-small cell lung cancer
 
 
NCT00705068: Combination Chemotherapy and Radiation Therapy in Treating Patients With Stage III or Stage IV Head and Neck Cancer (Paradigm Trial)

Active, not recruiting
3
330
US
carboplatin, cisplatin, docetaxel, fluorouracil, radiation therapy
University of Medicine and Dentistry New Jersey, Dana-Farber Cancer Institute
Head and Neck Cancer
12/11
 
ChiCTR-TRC-10000774: A multicenter randomized phase III trial to compare weekly usage with triweekly usage of docetaxel and cisplatin in concurrent chemoradio-therapy for patients with locally advaced non-small cell lun

Completed
3
200
 
The concurrent chemotherapy consisted of Docetaxel 60 mg/m2, on day 1 and Cisplatin 30mg/m2 , on day 1 and day 2, repeated every three weeks for a total of six weeks. Consolidation chemotherapy were performed after 4 to 6 weeks following the completion of concurrent chemoradiotherapy. Which consisted of of Docetaxel 35 mg/m2, on day 1 and Cisplatin 35mg/m2 , on day 1 and day 8, repeated every three weeks for a total of six weeks. TKI or pemetrexed were recommended to patients with progression of ;The concurrent chemotherapy consisted of Docetaxel and Cisplatin 20mg/m2 , on day 1, repeated every week for a total of six weeks. The same consolidation chemotherapy regime as A.
Beijing Cancer Hospital; Level of the institution：, No
Locally advanced non-small cell lung cancer
 
 
GETUG 13, NCT00104676 / 2005-001072-13: Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors

Active, not recruiting
3
263
Europe, US
bleomycin sulfate, cisplatin, etoposide, ifosfamide, oxaliplatin, paclitaxel
UNICANCER
Extragonadal Germ Cell Tumor, Teratoma, Testicular Germ Cell Tumor
03/12
12/24
SQUIRE, NCT00981058 / 2009-013838-25: First-line Treatment of Participants With Stage IV Squamous Non-Small Cell Lung Cancer With Necitumumab and Gemcitabine-Cisplatin

Checkmark IASLC-WCLC 2015
Aug 2015 - Aug 2015: IASLC-WCLC 2015
Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Checkmark ASCO 2015
More
Active, not recruiting
3
1093
Europe, Canada, US, RoW
Necitumumab, IMC-11F8, LY3012211, Gemcitabine, LY2334737, Cisplatin
Eli Lilly and Company, Parexel, PPD, Medidata Solutions, Laboratory Corporation of America, University of Colorado, Denver, Thermo Fisher Scientific FS, ICON Clinical Research, Pacific Biomarkers, Sysmex Inostics GmbH, Intertek
Non Small Cell Lung Cancer
06/13
06/24
ACTRN12609000369224: Randomised phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic radiation alone in high risk and advanced stage endometrial carcinoma: PORTEC-3

Active, not recruiting
3
680
 
The University of Sydney, National Health and Medical Research Council
Endometrial carcinoma
 
 
SAKK 16/00, NCT00030771: Preoperative Chemoradiotherapy vs. Chemotherapy Alone in NSCLC Patients

Completed
3
232
Europe, RoW
Chemotherapy, Radiotherapy, Surgery
Swiss Group for Clinical Cancer Research
Lung Cancer
04/14
09/23
2013-004303-39: Study with erlotinib compared to intercalated erlotinib with cisplatinum pemetrexed for advanced lung cancer

Ongoing
3
150
Europe
Tarceva, Cisplatine, Alimta, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Tarceva, Cisplatine, Alimta
Stichting NVALT Studies, Stichting NVALT Studies
Advanced non-small cell lung cancer, lung cancer, Diseases [C] - Cancer [C04]
 
 
O2, ChiCTR-TTRCC-14004093: Olanzapine versus aprepitant for the prevention of high dose cisplatin -induced nausea and vomiting: a randomized phase III trial.

Completed
3
320
 
Olanzapine
The Xiangya 2nd hospital Central South University; Level of the institution：, Jiangsu Haosen pharmaceutical Limited by Share Ltd
Vomiting
 
 
2014-005188-34: Phase III trial of laryngeal preservation comparating chemotherapy followed by radiotherapy to chemotherapy administrated during radiotherapy. Etude de phase III de préservation laryngée comparant une Chimiothérapie première suivie de Radiothérapie à une chimiothérapie administrée pendant la radiothérapie.

Not yet recruiting
3
440
Europe
CISPLATINE, DOCETAXEL, Fluorouracile, DOCETAXEL, Solution for infusion, Cisplatine Accord, Docetaxel Accord, Fluorouracile, CISPLATINE ACCORD
GORTEC, GORTEC
carcinomes épidermoïdes du larynx ou de l’hypopharynx localement avancé, carcinomes épidermoïdes du larynx ou de l’hypopharynx localement avancé, Diseases [C] - Cancer [C04]
 
 
NCT00324805: Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Checkmark ASCO 2016
May 2016 - May 2016: ASCO 2016
Checkmark From ECOG 1505 trial for lung cancer (adjuvant)
Feb 2016 - Feb 2016: From ECOG 1505 trial for lung cancer (adjuvant)
Checkmark Data-WCLC
More
Active, not recruiting
3
1501
Europe, Canada, US, RoW
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Gemcitabine Hydrochloride, dFdCyd, Difluorodeoxycytidine Hydrochloride, Gemcitabine HCI, Gemzar, LY-188011, LY188011, Laboratory Biomarker Analysis, Pemetrexed Disodium, Alimta, Almita, LY231514, N-[4-[2-(2-Amino-4,7-dihydro-4-oxo-1H-pyrrolo[2,3-d]pyrimidin-5-yl)ethyl]benzoyl]-L-glutamic Acid Disodium Salt, Questionnaire Administration, Vinorelbine Tartrate, Biovelbin, Eunades, KW-2307, Navelbine, Navelbine Ditartrate, NVB, Vinorelbine Ditartrate
National Cancer Institute (NCI), Cancer and Leukemia Group B, NCIC Clinical Trials Group, North Central Cancer Treatment Group, SWOG Cancer Research Network
Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIA Lung Non-Small Cell Carcinoma AJCC v7, Stage IIB Lung Non-Small Cell Carcinoma AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7
10/15
10/24
CINV, ChiCTR-IPR-14005265: Comparison of the effects of Palonosetron and Dexamethasone with and without Olanzapine to prevent the nausea and vomiting induced by 3-day cisplatin based chemotherapy in cancer patients: a multi cen

Recruiting
3
178
 
Olanzapine + Palonosetron + Dexamethsone ;Palonositron
the Fourth Affiliated Hospital of China Medical University; the Fourth Affiliated Hospital of China Medical Un, self - provided
malignant neoplasm
 
 
OS2006, NCT00470223 / 2006-003377-27: Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma

Active, not recruiting
3
318
Europe
cisplatin, doxorubicin hydrochloride, etoposide, ifosfamide, methotrexate, zoledronic acid, conventional surgery
UNICANCER, Novartis, Chugai Pharmaceutical, National Cancer Institute, France, SFCE, Ligue contre le cancer, France
Sarcoma
12/15
12/26
2004-000329-31: Continuous fluorouracil plus mitomycin C versus mitomycin C plus Cisplatin as chemotherapy combination in combined radiochemotherapy for locally advanced anal cancer. A phase II-III study

Ongoing
3
50
Europe
MITOMYCIN C*INIET 1FL 40MG, CISPLATINO MAYNE*EV 100MG100ML, MITOMYCIN C*INIET 1FL 40MG, CISPLATINO MAYNE*EV 100MG100ML
E.O.R.T.C. - EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER
Locally Advanced Anal Cancer
 
 
2004-005135-26: ORAL VINORELBINE AND CISPLATIN WITH CONCOMITANT RADIOTHERAPY FOLLOWED BY EITHER CONSOLIDATION THERAPY WITH ORAL VINORELBINE AND CISPLATIN PLUS BEST SUPPORTIVE CARE OR BEST SUPPORTIVE CARE ALONE IN STAGE III NON SMALL CELL LUNG CANCER (NSCLC): A RANDOMIZED PHASE III STUDY

Ongoing
3
376
Europe
Navelbine soft capsules, Cisplatin, Navelbine Soft capsule, Navelbine soft capsule, Navelbine Soft capsule, Navelbine soft capsule
Pierre Fabre Médicament
Stage III Non small cell lung cancer
 
 
2005-002736-10: Open, Randomised Phase II Study Assessing The Toxicity And Efficacy Of Platinum-Based Chemotherapy With Vitamin Supplementation In The Treatment Of Lung Cancer

Ongoing
3
84
Europe
Folic Acid, Gemcitabine, Vinblastine, Cisplatin, Vinorelbine, Docetaxel, Mitomycin-C, Etoposide, Vitamin B12, Carboplatin, Carboplatin
Royal Marsden Hospital
Non-small cell lung cancerSmall-cell lung cancerMalignant Mesothelioma (ICD classification code:C45.9)
 
 
2006-003503-39: Multicenter fase III undersøgelse af effekten af præoperativ (neoadjuverende) kemoterapi inden operation med efterfølgende adjuverende kemoterapi ved operabel NSCLC stadie IB, IIA; IIB, og IIIA/T3.

Ongoing
3
700
Europe
taxotere, carboplatin, cisplatin, Vinorelbine, L01CD02, L01XA02, L01X!01, Vinorelbine, taxotere, carboplatin, Cisplatin, Navirel, taxotere, carboplatin, Cisplatin, Navirel
Jens Benn Sorensen, Dept. oncology, Finsen Centre/National University Hospital
operable NSCLC.Pts are randomized to receive or not receive two courses of neoadjuvant chemotherapy before surgery
 
 
2007-001530-14: Essai de Phase III, Multicentrique, Randomisé, comparant la Chimiothérapie d’induction par Docétaxel, Cisplatine et 5-Fluorouracile (TPF) suivie d’une chimio-radiothérapie concomitante versus une chimio-radiothérapie concomitante seule, dans les cancers du nasopharynx classés T2b, T3, T4 et/ou avec envahissement ganglionnaire (>> N1)

Ongoing
3
30
Europe
TAXOTERE 80 mg TAXOTERE 20 mg
GORTEC,
Patients atteints de cancers du nasopharynx classés T2b; T3;T4 ; OMS II-III et /ou avec envahissement ganglionnaire (Nsupérieur ou égal à 1)
 
 
2007-003858-29: Prospektive multizentrische Phase-III-Studie zurambulanten Therapie mit Capecitabin versusCisplatin plus Capecitabin beim fortgeschrittenenAdenokarzinom der Gallenblase und Gallenwege(„CISCA-Studie“)

Ongoing
3
60
Europe
Xeloda, Xeloda, Cisplatin Ebewe, Xeloda, Cisplatin Ebewe
Universitätsklinikum Tübingen, Medizinische Klinik I
Karzinome der Gallenblase, Karzinome der extrahepatischen Gallengänge
 
 
2006-004726-91: A phase III randomised study comparing concomitant radiochemotherapy with cisplatin and docetaxel as induction versus consolidation treatment in patients with locally advanced unresectable non-small cell lung cancer

Ongoing
3
246
Europe
taxotere, Docetaxel, Cisplatin, Docetaxel, Cisplatin
CHRU de Lille
Unresectable non metastatic stage III non small cell lung carcinoma eligible for concomitant radiochemotherapy
 
 
2008-005760-14: Etude de phase III randomisée, multicentrique comparant une chimiothérapie d’induction par TPF suivie d’une association radiothérapie Erbitux® versus une radiochimiothérapie concomitante chez des patients présentant un carcinome épidermoïde des VADS localement évolué inopérable

Ongoing
3
284
Europe
CETUXIMAB, Cisplatine, TAXOTERE 80mg, fluorouracile, LO1XC06, DOCETAXEL, 5FU, ERBITUX, CISPLATINE IBD3 PHARMA CONSULTING, TAXOTERE 80mg, FLUOROURACILE DAKOTA, ERBITUX, CISPLATINE IBD3 PHARMA CONSULTING, TAXOTERE 80mg, FLUOROURACILE DAKOTA
GORTEC
Cet essai sera proposé aux patients porteurs de carcinome épidermoïde histologiquement prouvé de la cavité buccale, de l\'oropharynx, du larynx, ou de l\'hypopharynx, de stadeIV non métastatique (carcinome localement évolué inopérable).
 
 
2007-002644-21: A randomized phase III study of adjuvant chemotherapy in patients with completely resected Non-Small-Cell Lung Cancer and low-risk for recurrence: NVALT-8A

Ongoing
3
864
Europe
cisplatine, Vinorelbine, Gemzar, Alimta, Cisplatine, Vinorelbine, Gemzar, Alimta, Cisplatine, Vinorelbine, Gemzar, Alimta
UMCG
This is a randomized multicenter phase III study. Patient with a low SUV of the primary tumor prior to surgery will be randomised to four cycles of cisplatin-based chemotherapy or observation in a non-inferiority design.
 
 
2007-007949-13: Multicenter phase III randomized study of cisplatin and etoposide with or without bevacizumab as first-line treatment in extensive stage (ED) small cell lung cancer (SCLC)

Ongoing
3
206
Europe
AVASTIN, AVASTIN
GRUPPO ONCOLOGICO ITALIANO DI RICERCA
Previously untreated patients with extended small cells lung cancer (SCLC).
 
 
2011-001858-28: A clinical trial for people who have cancer of the food pipe and junction of the food pipe and stomach, to compare chemotherapy before and after surgery, with chemotherapy with radiotherapy before surgery.

Ongoing
3
378
Europe
Epirubicin, Cisplatin, 5 Fluorouracil, Capecitabine, Paclitaxel, Carboplatin, Oxaliplatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin, Carboplatin, Cisplatin, Epirubicin, Capecitabine, Fluorouracil, Paclitaxel, Eloxatin
ICORG, ICORG- All Ireland Cooperative Oncology Research Group, ICORG,
Adenocarcinoma of the oesophagus and oesophago-gastric junction
 
 
2013-004321-83: CUP Trial Ensayo CUP

Ongoing
3
40
Europe
Cisplatino Ferrer Farma 1mg/ml, concentrado para solución para perfusión, Gemcitabina STADA polvo para solución para perfusión, Cisplatino Ferrer Farma 1mg/ml, concentrado para solución para perfusión, Gemcitabina STADA polvo para solución para perfusión
Institut Català d\'Oncologia (ICO), Institu Català d'Oncologia (ICO)
Carcinomas of an unknown primary site (CUP) Carcinomas de origen primario desconocido
 
 
2013-004039-60: A study to evaluate a risk-adapted treatment of extra cranial malignant germ cell in children, adolescent and young adult Etude évaluant un traitement adapté au pronostic dans les tumeurs germinales malignes extra-crâniennes de l’enfant, de l’adolescent et du jeune adulte

Ongoing
3
94
Europe
cisplatin, vinblastine, bleomycin, etoposide, ifosfamide,
CENTRE LEON BERARD, ENFANCE ET SANTE, 111 DES ARTS
extra cranial non seminomateous malignant germ cell tumour in child, adolescent and young adult tumeurs germinales malignes non séminomateuses (TGMNS) extra-crâniennes chez l\'enfant, l\'adolescent et le jeune adulte
 
 
NCT00304070: Cisplatin-Based Chemotherapy and/or Surgery in Treating Young Patients With Adrenocortical Tumor

Completed
3
78
Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Conventional Surgery, Doxorubicin Hydrochloride, 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8, 9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)- (9CI), ADM, Adriacin, Adriamycin, Adriamycin Hydrochloride, Adriamycin PFS, Adriamycin RDF, ADRIAMYCIN, HYDROCHLORIDE, Adriamycine, Adriblastina, Adriblastine, Adrimedac, Chloridrato de Doxorrubicina, DOX, DOXO-CELL, Doxolem, Doxorubicin HCl, Doxorubicin.HCl, Doxorubin, Farmiblastina, FI 106, FI-106, hydroxydaunorubicin, Rubex, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim-aafi, Filgrastim-ayow, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tevagrastim, Mitotane, (o,p)-DDD, 1, 1-Dichloro-2-(o-chlorophenyl)-2-(p-chlorophenyl)ethane, 1-Chloro-2-[2,2-dichloro-1-(4-chlorophenyl)ethyl]benzene, 2, 2-Bis(2-chlorophenyl-4-chlorophenyl)-1,1-dichloroethane, 2, 4'-Dichlorodiphenyldichloroethane, CB 313, CB-313, Chloditan, Chlodithane, DDD, Ethane, 2-(o-chlorophenyl)-2-(p-chlorophenyl)-1,1-dichloro-, Khloditan, Lisodren, Lysodren, Mytotan, o,p' - DDD, o,p'-DDD, Ortho,para-DDD, WR-13045, Pegfilgrastim, Filgrastim SD-01, filgrastim-SD/01, Fulphila, HSP-130, Jinyouli, Neulasta, Neulastim, Nyvepria, PEG-filgrastim, Pegcyte, Pegfilgrastim Biosimilar HSP-130, Pegfilgrastim Biosimilar Nyvepria, Pegfilgrastim Biosimilar Pegcyte, Pegfilgrastim Biosimilar PF-06881894, Pegfilgrastim Biosimilar Udenyca, Pegfilgrastim Biosimilar Ziextenzo, pegfilgrastim-apgf, pegfilgrastim-bmez, pegfilgrastim-cbqv, Pegfilgrastim-jmdb, PF-06881894, SD-01, SD-01 sustained duration G-CSF, Udenyca, Ziextenzo
Children's Oncology Group, National Cancer Institute (NCI)
Stage I Adrenal Cortical Carcinoma AJCC v7, Stage II Adrenal Cortical Carcinoma AJCC v7, Stage III Adrenal Cortical Carcinoma AJCC v7, Stage IV Adrenal Cortical Carcinoma AJCC v7
12/15
06/23
GOG-0258, NCT00942357: Carboplatin and Paclitaxel With or Without Cisplatin and Radiation Therapy in Treating Patients With Stage I, Stage II, Stage III, or Stage IVA Endometrial Cancer

Active, not recruiting
3
813
Canada, US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Internal Radiation Therapy, BRACHYTHERAPY, internal radiation, Internal Radiation Brachytherapy, Radiation Brachytherapy, Paclitaxel, Anzatax, Asotax, Bristaxol, Praxel, Taxol, Taxol Konzentrat, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, irradiation, Radiation, Radiotherapeutics, RADIOTHERAPY, RT, Therapy, Radiation
Gynecologic Oncology Group, National Cancer Institute (NCI)
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage IA Uterine Corpus Cancer AJCC v7, Stage IB Uterine Corpus Cancer AJCC v7, Stage II Uterine Corpus Cancer AJCC v7, Stage IIIA Uterine Corpus Cancer AJCC v7, Stage IIIB Uterine Corpus Cancer AJCC v7, Stage IIIC Uterine Corpus Cancer AJCC v7, Stage IVA Uterine Corpus Cancer AJCC v7
02/16
07/24
Randomized study of Genexol-PM combined with Cisplatin in advanced NSCLC, ChiCTR-IPR-15006252: A Randomized, Open, Multicenter Trial of Genexol-PM or Paclitaxel Injection combined with Cisplatin for first-line therapy of advanced Non-Small Cell Lung Cancer(NSCLC)

Recruiting
3
426
 
Genexol-PM+Cisplatin ;Paclitaxel Injection + Cisplatin
Guangdong General Hospital; Shanghai Chest Hospital; Jiangsu Cancer Hospital; Shanghai Yizhong Bio-technology Co., Ltd, self-financing
Non-Small Cell Lung Cancer(NSCLC)
 
 
2005-000838-21: RANDOMIZED STUDY OFRADIOTHERAPY WITH CONCOMITANT BOOST (RTcb) AND CONCURRENT LOW DOSE CISPLATINVSRTcb AND CISPLATIN + FLUOROURACILIN ADVANCED HNSCC

Ongoing
3
344
Europe
Solution for infusion
ISTITUTO NAZIONALE PER LA CURA TUMORI
Head and neck cancer
 
 
NCT00085735 / 2009-010004-28: Comparison of Radiation Therapy Regimens in Combination With Chemotherapy in Treating Young Patients With Newly Diagnosed Standard-Risk Medulloblastoma

Active, not recruiting
3
549
Europe, Canada, US, RoW
Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Craniospinal Irradiation, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Involved-Field Radiation Therapy, IFRT, Involved field radiotherapy, Laboratory Biomarker Analysis, Lomustine, 1-(2-Chloroethyl)-3-cyclohexyl-1-nitrosourea, 1-Nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-, Belustin, Belustine, CCNU, Cecenu, CeeNU, Chloroethylcyclohexylnitrosourea, Citostal, Lomeblastin, Lomustinum, Lucostin, Lucostine, N-(2-Chloroethyl)-N'-cyclohexyl-N-nitrosourea, Prava, RB-1509, WR-139017, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Irradiate, Irradiated, Irradiation, RADIATION, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Untreated Childhood Medulloblastoma
03/16
 
JCOG0509, UMIN000000720: Japanese A Multicenter, Randomized, Controlled Phase III Study of Amrubicin + Cisplatin (AP) Versus Irinotecan + Cisplatin (IP) for Advanced Small Cell Lung Cancer

Completed
3
282
Japan
irinotecan - Generic mfg., cisplatin - Generic mfg., Calsed (amrubicin) - Sumitomo Pharma, BMS
Japan Clinical Oncology Group (JCOG), Ministry of Health, Labour and Welfare
Advanced Small Cell Lung Cancer
 
 
2010-023525-38: ENSAYO EN FASE III ALEATORIZADO DE CISPLATINO MÁS PACLITAXEL CON Y SIN BEVACIZUMAB FRENTE AL DOBLETE SIN PLATINO, TOPOTECAN MÁS PACLITAXEL, CON Y SIN BEVACIZUMAB, EN CARCINOMA DE CÉRVIX EN ESTADIO IVB, RECURRENTE O PERSISTENTE

Ongoing
3
35
Europe
cisplatino, Topotecan, Paclitaxel, PR2, PR3, PR4, AVASTIN 25 mg/ml concentrado para solución para perfusión, AVASTIN 25 mg/ml concentrado para solución para perfusión
Grupo Español de Investigación en Cáncer de Ovario
carcinoma de cérvix en estadio IVB, recurrente o persistente
 
 
2007-006250-25: A Phase III, Randomised, Double-blind, Multi-centre, Parallel Group Study to Compare the Efficacy of Cediranib (AZD2171, RECENTIN™) (30 mg) When Added to Gemcitabine and Cisplatin versus the Efficacy of Placebo When Added to Gemcitabine and Cisplatin in Patients with Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.

 
3
60
Europe
RECENTIN, AZD2171,
ASTRAZENECA
Locally Advanced or Metastatic (Stage IIIb/IV) Non Small Cell Lung Cancer.
 
 
NCT02265692: Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer

Recruiting
3
253
US, Canada, RoW
therapeutic conventional surgery, cisplatin, CACP, CDDP, CPDD, DDP, fluorouracil, 5-fluorouracil, 5-Fluracil, 5-FU, vincristine sulfate, leurocristine sulfate, VCR, Vincasar PFS, doxorubicin hydrochloride, ADM, ADR, Adria, irinotecan hydrochloride, Campto, Camptosar, CPT-11, irinotecan, U-101440E, temsirolimus, CCI-779, cell cycle inhibitor 779, Torisel, liver transplantation, laboratory biomarker analysis
National Cancer Institute (NCI)
Childhood Hepatoblastoma, Stage I Childhood Liver Cancer, Stage II Childhood Liver Cancer, Stage III Childhood Liver Cancer, Stage IV Childhood Liver Cancer
06/16
 
ASCEND-4, NCT01828099 / 2013-000319-26: LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Checkmark ASCEND-4 trial in ALK+ NSCLC
Apr 2017 - Apr 2017: ASCEND-4 trial in ALK+ NSCLC
Checkmark ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Sep 2016 - Sep 2016: ASCEND-4 data in patients with ALK+ non-small cell lung cancer (NSCLC)
Completed
3
376
Europe, Japan, RoW
Ceritinib, LDK378, Pemetrexed, Cisplatin, Carboplatin
Novartis Pharmaceuticals
Non-Small Cell Lung Cancer
06/16
01/24
ChiCTR-TRC-13003547: A multi center randomized phase III clinical study of selective lymph nodes radiotherapy vs involved field radiotherapy combined with concurrent S-1 and cisplatin chemotherapy in patients with locally advanced esophageal squamous carcinoma

Recruiting
3
460
 
involved field radiotherapy combined with concurrent S-1 and cisplatin chemotherapy ;selective lymph nodes radiotherapy
Shandong Cancer Hospital; Shandong Cancer Hospital, Other
locally advanced esophageal squamous carcinoma
 
 
acns0333, NCT00653068: Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System

Completed
3
70
Canada, US, RoW
3-Dimensional Conformal Radiation Therapy, 3-dimensional radiation therapy, 3D Conformal, 3D CONFORMAL RADIATION THERAPY, 3D CRT, 3D radiotherapy, 3D-CRT, Conformal Therapy, Radiation Conformal Therapy, Radiation, 3D Conformal, Three dimensional external beam radiation therapy (procedure), Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP 16213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, Folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Childhood Atypical Teratoid/Rhabdoid Tumor
09/16
03/24
NCT00085202: Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor

Completed
3
416
Canada, US, RoW
filgrastim, Neupogen(R), G-CSF, cisplatin, Platinol-AQ(R), cyclophosphamide, Cytoxan(R), vincristine, Oncovin(R), autologous hematopoietic stem cell transplantation, autologous HSCT, radiation therapy, RT, Craniospinal radiotherapy
St. Jude Children's Research Hospital
Brain and Central Nervous System Tumors
12/16
12/23
COG-ACNS0334, NCT00336024: Combination Chemotherapy Followed By Peripheral Stem Cell Transplant in Treating Young Patients With Newly Diagnosed Supratentorial Primitive Neuroectodermal Tumors or High-Risk Medulloblastoma

Active, not recruiting
3
91
Canada, US, RoW
Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim-aafi, Filgrastim-ayow, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tevagrastim, Laboratory Biomarker Analysis, Leucovorin Calcium, Adinepar, Calcifolin, Calcium (6S)-Folinate, Calcium Folinate, Calcium Leucovorin, Calfolex, Calinat, Cehafolin, Citofolin, Citrec, Citrovorum Factor, Cromatonbic Folinico, Dalisol, Disintox, Divical, Ecofol, Emovis, Factor, Citrovorum, Flynoken A, Folaren, Folaxin, FOLI-cell, Foliben, Folidan, Folidar, Folinac, Folinate Calcium, folinic acid, Folinic Acid Calcium Salt Pentahydrate, Folinoral, Folinvit, Foliplus, Folix, Imo, Lederfolat, Lederfolin, Leucosar, leucovorin, Rescufolin, Rescuvolin, Tonofolin, Wellcovorin, Methotrexate, Abitrexate, Alpha-Methopterin, Amethopterin, Brimexate, CL 14377, CL-14377, Emtexate, Emthexat, Emthexate, Farmitrexat, Fauldexato, Folex, Folex PFS, Lantarel, Ledertrexate, Lumexon, Maxtrex, Medsatrexate, Metex, Methoblastin, Methotrexate LPF, Methotrexate Methylaminopterin, Methotrexatum, Metotrexato, Metrotex, Mexate, Mexate-AQ, MTX, Novatrex, Rheumatrex, Texate, Tremetex, Trexeron, Trixilem, WR-19039, Quality-of-Life Assessment, Quality of Life Assessment, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Anaplastic Medulloblastoma, Medulloblastoma, Supratentorial Embryonal Tumor, Not Otherwise Specified, Untreated Childhood Supratentorial Primitive Neuroectodermal Tumor
12/16
12/28
ChiCTR-TRC-11001539: Recombinant endostatin (Sulijia) combined chemotherapy with Vinorelbine and Cisplatin (NP) plus maintenance therapy with Sulijia for advanced Non-small Cell Lung Cancer: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III trial

Recruiting
3
560
 
Placebo combined chemotherapy with Vinorelbine and Cisplatin (NP) ;Sulijia combined chemotherapy with Vinorelbine and Cisplatin (NP)
Cancer Institute & Hospital Chinese Academy of Medical Science; Science and Technology Department of Jiangsu Province, Jiangsu Wuzhong Pharmaceutical Group Inc.
Advanced or metastatic (IV) NSCLC
 
 
ACTRN12610000732088: A Phase III trial of adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone

Active, not recruiting
3
900
 
The University of Sydney, National Health & Medical Research Council
Locally advanced cervical cancer
 
 
2016-004383-19: Randomized trial of avelumab-cetuximab-Radiotherapy versus standards of care in the head and neck cancers Essai randomisé avelumab-cetuximab-radiotherapy versus traitements standards dans les cancers tête et cou

Ongoing
3
688
Europe
Avelumab, cetuximab, cisplatine, Infusion, Solution for injection/infusion, Solution for infusion, ERBITUX, CISPLATINE MYLAN
GORTEC, GORTEC, MERCK GROUP
Squamous cell carcinoma, previously untreated Stage III, stage IVa (i.e. operable, but not operated) or IVb (non resectable) Oral cavity, oropharynx, hypopharynx or larynx Carcinome épidermoïde jamais traité Stade III, stade IVa (i.e. opérable, mais non opéré) ou IVb (non résécable) Cavité orale, oropharynx, hypopharynx ou larynx, Locally advanced squamous cell carcinoma of the head and neck Carcinome épidermoïde localement avancé de la tête et du cou, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-189, NCT02578680 / 2015-003694-15: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/)

Checkmark From KEYNOTE-189 trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC at ESMO – IO 2019
Dec 2019 - Dec 2019: From KEYNOTE-189 trial in combination with pemetrexed and platinum chemotherapy for 1L NSCLC at ESMO – IO 2019
Checkmark Data from KEYNOTE-189 trial for NSCLC at IASLC-WCLC 2019
Sep 2019 - Sep 2019: Data from KEYNOTE-189 trial for NSCLC at IASLC-WCLC 2019
Checkmark Updated data in combination with Alimta for metastatic nonsquamous 1L NSCLC
More
Completed
3
616
NA
Pembrolizumab 200 mg, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg, Saline solution
Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
11/17
06/23
2017-002311-34: Phase 3 Study of Pembro with/without Epacadostat in 1L Urothelial Carcinoma Estudio de fase 3 de pembrolizumab con/sin epacadostat en el tratamiento de primera línea del carcinoma urotelial

Ongoing
3
650
Europe
pembrolizumab, Epacadostat, MK-3475, INCB024360, Solution for infusion, Tablet
Incyte Corporation, Incyte Corporation, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
Bladder cancer Cáncer de vejiga, Bladder cancer Cáncer de vejiga, Diseases [C] - Cancer [C04]
 
 
2012-000092-16: Study evaluating two maintenance strategies (continuous and according to the response of chemotherapy in advanced lung cancer) Etude évaluant deux stratégies de maintenance (maintenance de continuation et maintenance en fonction de la réponse à la chimiothérapie) dans le cancer du poumon de stade avancé

Not yet recruiting
3
918
Europe
NA, NA, Solution for infusion, Powder for solution for infusion, Alimta, Cisplatin, Gemzar, Carboplatin
IFCT, IFCT
Advanced non squamous non small cell lung cancer Cancer du poumon non à petites cellules non-épidermoïde de stade avancé, Lung cancer Cancer du poumon, Diseases [C] - Cancer [C04]
 
 
ACTRN12612001211853: TROG 11.03 A Randomised Phase III Trial of High Dose Palliative Radiotherapy (HDPRT) Versus Concurrent Chemotherapy + HDPRT (C-HDPRT) in Patients with Good Performance Status, Locally Advanced/Small Volume Metastatic Non Small Cell Lung Cancer (NSCLC) Not Suitable for Radical Chemo-Radiotherapy (P_LUNG GP)

Active, not recruiting
3
130
 
Trans Tasman Radiation Oncology Group, Cancer Australia
Non Small Cell Lung Cancer (NSCLC)
 
 
NCT03366883: Paclitaxel, Cisplatin,5-FU vs. Radiotherapy Plus Paclitaxel, Cisplatin as Preoperative Therapy for Locally Advanced ESC

Not yet recruiting
3
420
RoW
Paclitaxel, Cisplatin Plus 5-FU (TCF), radiochemotherapy
Tianjin Medical University Cancer Institute and Hospital, Shanghai Chest Hospital, Henan Cancer Hospital, The First Affiliated Hospital with Nanjing Medical University, First Affiliated Hospital of Chongqing Medical University, The First Affiliated Hospital of Anhui Medical University
Esophageal Cancer Stage IIB, Esophageal Cancer Stage III
02/18
12/22
PERS, NCT03006614: Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer

Recruiting
3
320
RoW
NVB, vinorelbine, EPI, epirubicin, DDP, cisplatin, CAP, capecitabine, GEM, gemcitabine, H, Trastuzumab, CTX, cyclophosphamidem, T, docetaxel
Shi Yanxia
Breast Cancer Model, Effects of Chemotherapy, Breast Cancer
03/18
03/23
NCT00588770: Chemotherapy With or Without Bevacizumab in Treating Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Checkmark ASCO 2015
May 2015 - May 2015: ASCO 2015
Active, not recruiting
3
403
US, RoW
Bevacizumab, ABP 215, Anti-VEGF, Anti-VEGF Humanized Monoclonal Antibody, Anti-VEGF Monoclonal Antibody SIBP04, Anti-VEGF rhuMAb, Avastin, BAT 1706, BAT-1706, BAT1706, BAT1706 Biosimilar, Bevacizumab awwb, Bevacizumab Biosimilar ABP 215, Bevacizumab Biosimilar BAT1706, Bevacizumab Biosimilar BEVZ92, Bevacizumab Biosimilar BI 695502, Bevacizumab Biosimilar CBT 124, Bevacizumab Biosimilar CT-P16, Bevacizumab Biosimilar FKB238, Bevacizumab Biosimilar GB-222, Bevacizumab Biosimilar HD204, Bevacizumab Biosimilar HLX04, Bevacizumab Biosimilar IBI305, Bevacizumab Biosimilar LY01008, Bevacizumab Biosimilar MIL60, Bevacizumab Biosimilar Mvasi, Bevacizumab Biosimilar MYL-1402O, Bevacizumab Biosimilar QL 1101, Bevacizumab Biosimilar QL1101, Bevacizumab Biosimilar RPH-001, Bevacizumab Biosimilar SCT501, Bevacizumab Biosimilar Zirabev, Bevacizumab-adcd, Bevacizumab-awwb, Bevacizumab-bvzr, BP102, BP102 Biosimilar, CT-P16, HD204, Immunoglobulin G1 (Human-Mouse Monoclonal rhuMab-VEGF Gamma-Chain Anti-Human Vascular Endothelial Growth Factor), Disulfide With Human-Mouse Monoclonal rhuMab-VEGF Light Chain, Dimer, Mvasi, MYL-1402O, QL1101, Recombinant Humanized Anti-VEGF Monoclonal Antibody, rhuMab-VEGF, SCT501, SIBP 04, SIBP-04, SIBP04, Vegzelma, Zirabev, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Docetaxel, Docecad, RP 56976, RP56976, Taxotere, Taxotere Injection Concentrate, Fluorouracil, 5 Fluorouracil, 5 Fluorouracilum, 5 FU, 5-Fluoro-2,4(1H, 3H)-pyrimidinedione, 5-Fluorouracil, 5-Fluracil, 5-Fu, 5FU, AccuSite, Carac, Fluoro Uracil, Fluouracil, Flurablastin, Fluracedyl, Fluracil, Fluril, Fluroblastin, Ribofluor, Ro 2-9757, Ro-2-9757, Laboratory Biomarker Analysis
National Cancer Institute (NCI)
Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Hypopharyngeal Squamous Cell Carcinoma, Recurrent Laryngeal Squamous Cell Carcinoma, Recurrent Laryngeal Verrucous Carcinoma, Recurrent Lip and Oral Cavity Squamous Cell Carcinoma, Recurrent Neck Squamous Cell Carcinoma of Unknown Primary, Recurrent Oral Cavity Verrucous Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Sinonasal Squamous Cell Carcinoma, Salivary Gland Squamous Cell Carcinoma, Stage IV Hypopharyngeal Squamous Cell Carcinoma AJCC v7, Stage IV Major Salivary Gland Cancer AJCC v7, Stage IVA Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Laryngeal Verrucous Carcinoma AJCC v7, Stage IVA Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVA Major Salivary Gland Cancer AJCC v7, Stage IVA Oral Cavity Cancer AJCC v6 and v7, Stage IVA Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVA Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Laryngeal Verrucous Carcinoma AJCC v7, Stage IVB Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVB Major Salivary Gland Cancer AJCC v7, Stage IVB Oral Cavity Cancer AJCC v6 and v7, Stage IVB Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVB Sinonasal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Laryngeal Verrucous Carcinoma AJCC v7, Stage IVC Lip and Oral Cavity Squamous Cell Carcinoma AJCC v6 and v7, Stage IVC Major Salivary Gland Cancer AJCC v7, Stage IVC Oral Cavity Cancer AJCC v6 and v7, Stage IVC Oropharyngeal Squamous Cell Carcinoma AJCC v7, Stage IVC Sinonasal Squamous Cell Carcinoma AJCC v7, Tongue Carcinoma
06/18
02/25
2018-000580-90: Multicenter randomized open-label phase III trial of Adjuvant Chemotherapy vs. observation or mitotane after primary surgical resection of localized Studio multicentrico, randomizzato, in aperto di fase III volto a valutare l’attività di chemioterapia adiuvante versus osservazione/mitotane dopo chirurgia di prima linea in pazienti affetti da carcinoma corticosurrenale localizzato ad alto rischio di recidiva (ACACIA)

Ongoing
3
200
Europe
CISPLATINO, etoposide, mitotano, [CISPLATINO], [etoposide], [mitotano], Solution for infusion, Solution for injection, Tablet, CISPLATINO ACCORD HEALTHCARE ITALIA - 1MG/ML CONCENTRATO PER SOLUZIONE PER INFUSIONE 1 FLACONCINO IN VETRO DA 10 ML, ETOPOSIDE TEVA - 1 FLACONE 10 ML 20MG/ML, LYSODREN - 500 MG-COMPRESSE-USO ORALE-FLACONE(HDPE) 100 COMPRESSE
AZIENDA SOCIO SANITARIA TERRITORIALE DEGLI SPEDALI CIVILI DI BRESCIA, AIFA - Italian Medicines Agency
localized Adrenocortical CarcInomA with high risk of recurrence pazienti affetti da carcinoma corticosurrenale localizzato ad alto rischio di recidiva, Adrenocortical CarcInomA carcinoma corticosurrenale, Diseases [C] - Cancer [C04]
 
 
NCT00554788: Combination Chemotherapy, Autologous Stem Cell Transplant, and/or Radiation Therapy in Treating Young Patients With Extraocular Retinoblastoma

Active, not recruiting
3
60
Canada, US, RoW
Autologous Bone Marrow Transplantation, ABMT, Autologous Blood and Marrow Transplantation, Autologous Bone Marrow Transplant, Autologous Marrow Transplantation, Autologous Hematopoietic Stem Cell Transplantation, AHSCT, Autologous, Autologous Hematopoietic Cell Transplantation, Autologous Stem Cell Transplant, Autologous Stem Cell Transplantation, Stem Cell Transplantation, Autologous, Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, Etoposide, Demethyl Epipodophyllotoxin Ethylidine Glucoside, EPEG, Lastet, Toposar, Vepesid, VP 16, VP 16-213, VP-16, VP-16-213, VP16, Filgrastim, Filgrastim-aafi, Filgrastim-ayow, G-CSF, Neupogen, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tevagrastim, In Vitro-Treated Peripheral Blood Stem Cell Transplantation, in vitro-treated PBPC transplantation, in vitro-treated peripheral blood progenitor cell transplantation, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Thiotepa, 1,1',1''-Phosphinothioylidynetrisaziridine, Girostan, N,N', N''-Triethylenethiophosphoramide, Oncotiotepa, STEPA, Tepadina, TESPA, Tespamin, Tespamine, Thio-Tepa, Thiofosfamide, Thiofozil, Thiophosphamide, Thiophosphoramide, Thiotef, Tifosyl, TIO TEF, Tio-tef, Triethylene Thiophosphoramide, Triethylenethiophosphoramide, Tris(1-aziridinyl)phosphine sulfide, TSPA, WR 45312, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Extraocular Retinoblastoma
06/18
12/24
RTOG-1016, NCT01302834: Radiation Therapy With Cisplatin or Cetuximab in Treating Patients With Oropharyngeal Cancer

Active, not recruiting
3
987
Canada, US
cetuximab, cisplatin, IMRT, intensity-modulated radiotherapy, intensity-modulated radiation therapy
Radiation Therapy Oncology Group, National Cancer Institute (NCI), NRG Oncology
Head and Neck Cancer, Precancerous Condition
07/18
 
KEYNOTE-669, NCT03358472 / 2017-001338-24: Pembrolizumab Plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (/ECHO-304)

Active, not recruiting
3
89
Europe, Canada, Japan, US, RoW
Pembrolizumab, MK-3475, Epacadostat, INCB024360, Cetuximab, Cisplatin, Carboplatin, 5-Fluorouracil
Incyte Corporation, Merck Sharp & Dohme LLC
Head and Neck Cancer
07/18
12/24
NCT02875457: Apatinib as the Maintenance Therapy for Extensive Stage Small Cell Lung Cancer After Combined With Etoposide/Cisplatin

Not yet recruiting
3
100
RoW
apatinib;etoposide and cisplatin, placebo;etoposide and cisplatin
Third Military Medical University
Small Cell Lung Cancer
09/18
09/23
MYSTIC, NCT02453282 / 2015-001279-39: Phase III Open Label First Line Therapy Study of MEDI 4736 (Durvalumab) With or Without Tremelimumab Versus SOC in Non Small-Cell Lung Cancer (NSCLC)

Checkmark From MYSTIC trial in 1L mNSCLC
Apr 2020 - Apr 2020: From MYSTIC trial in 1L mNSCLC
Checkmark Results for metastatic NSCLC [MYSTIC]
Dec 2018 - Dec 2018: Results for metastatic NSCLC [MYSTIC]
Checkmark OS data from MYSTIC trial in 1L NSCLC
More
Active, not recruiting
3
1118
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), MEDI4736 (Durvalumab)+Tremelimumab, Paclitaxel + Carboplatin, Platinum based Standard of Care Chemotherapy, Gemcitabine + Cisplatin, Gemcitabine + Carboplatin, Pemetrexed + Cisplatin, Pemetrexed + Carboplatin, Tremelimumab
AstraZeneca
Non-Small-Cell Lung Carcinoma NSCLC
10/18
12/24
PORTEC-3, NCT00411138 / 2007-004917-33: Randomized Trial of Radiation Therapy With or Without Chemotherapy for Endometrial Cancer

Active, not recruiting
3
670
Europe
Radiation Therapy, RT, 3D conformal radiotherapy, IMRT, brachytherapy, cisplatin, Cisplatine, carboplatin, Carboplatine, Carbotaxol, Paclitaxel, Taxol, Taxolcarbo
Leiden University, Cancer Research UK, Australia New Zealand Gynaecological Oncology Group, NCIC Clinical Trials Group, Mario Negri Institute for Pharmacological Research, UNICANCER
Endometrial Cancer
11/18
12/24
CRITICS, NCT00407186 / 2006-004130-32: Randomized Phase III Trial of Adjuvant Chemotherapy or Chemoradiotherapy in Resectable Gastric Cancer

Active, not recruiting
3
788
Europe
cisplatin+capecitabine, radiotherapy, epirubicin+cisplatin+capecitabine
Dutch Colorectal Cancer Group, The Netherlands Cancer Institute, Roche Pharma AG
Gastric Cancer
12/18
12/25
2017-004444-38: Study in Gallbladder or bile duct cancer comparing chemotherapy with gemcitabine plus cisplatin before and after radical liver resection with direct radical liver resection followed by chemotherapy or no chemotherapy (physician's decision) - A Phase III study of the German Gallbladder Cancer Registry Studie bei Gallenblasen- oder Gallengangskarzinom die Chemotherapie mit Gemcitabin plus Cisplatin vor und nach radikaler Leberresektion vergleicht mit direkter radikaler Leberresektion gefolgt von Chemotherapie oder keiner Chemotherapie (Arztentscheidung) - Eine Phase III Studie des Deutschen Gallenblasenkarzinom-Registers

Not yet recruiting
3
300
Europe
Cisplatin, Gemcitabin, Concentrate for solution for infusion, Powder for solution for infusion
Krankenhaus Nordwest gGmbH, Deutsche Forschungsgemeinschaft
incidental gallbladder carcinoma (IGBC) or biliary tract cancer (BTC) (intrahepatic cholangiocarcinoma (ICC)/ extrahepatic cholangiocarcinoma (ECC)), gallbladder carcinoma or biliary-tract cancer, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-048, NCT02358031 / 2014-003698-41: A Study of Pembrolizumab (MK-3475) for First Line Treatment of Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck (MK-3475-048/)

Checkmark Data from KEYNOTE-048 trial for SCCHN at ESMO 2020
Sep 2020 - Sep 2020: Data from KEYNOTE-048 trial for SCCHN at ESMO 2020
Checkmark KEYNOTE-048 trial at ASCO 2019
May 2019 - May 2019: KEYNOTE-048 trial at ASCO 2019
Checkmark KEYNOTE-048 trial for 1L SCCHN
More
Completed
3
882
NA
Pembrolizumab, KEYTRUDA®, MK-3475, Cisplatin, Carboplatin, 5-FU, Cetuximab
Merck Sharp & Dohme LLC
Recurrent Head and Neck Cancer, Metastatic Head and Neck Cancer
02/19
07/23
2018-001811-59: This is a Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment followed by Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Not yet recruiting
3
1050
Europe
durvalumab, MEDI4736, Concentrate for solution for infusion, Remicade 100mg powder for concentrate for solution for infusion, Celicept 250mg Capsules, Micofenolato Mofetile, Mycophenolate mofetil Sandoz 250 mg, Inflectra 100 mg powder for concentrate for solution for infusion
AstraZeneca AB, ASTRAZENECA AB, AstraZeneca AB
Patients with histologically or cytologically documented muscle-invasive transitional cell carcinoma (TCC) of the bladder, Muscle Invasive Bladder Cancer (T2-T4a) in stage II and IIIA without lymph node involvement, Diseases [C] - Cancer [C04]
 
 
KEYNOTE-189 Japan Extension study, NCT03950674 / 2015-003694-15: Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension Study

Checkmark Presentation of data from KEYNOTE-189 trial for 1L non squamous NSCLC at ESMO 2022
Sep 2022 - Sep 2022: Presentation of data from KEYNOTE-189 trial for 1L non squamous NSCLC at ESMO 2022
Checkmark Results from KEYNOTE-189 trial for 1L nonsquamous non-small cell lung cancer at ESMO
Sep 2022 - Sep 2022: Results from KEYNOTE-189 trial for 1L nonsquamous non-small cell lung cancer at ESMO
Checkmark From KEYNOTE-189 in 2L NSCLC
More
Completed
3
40
Japan
Pembrolizumab 200 mg, Cisplatin, Carboplatin, Pemetrexed, Folic acid 350-1000 μg, Vitamin B12 1000 μg, Dexamethasone 4 mg, Saline solution
Merck Sharp & Dohme LLC
Non-Small-Cell Lung Carcinoma
05/19
06/23
ChiCTR-IIR-17012830: A prospective phase III clinical trial to compare different treatment (IMRT+TPregimen, IMRT+weekly cisplatin and 3DCRT+weekly cisplatin) in treating late stage cervical cancer with concurrent chemoradiotherapy

Recruiting
3
150
 
using 3D-CRT technique ;using IMRT technique ;using TP chemotherapy regimen
Tumor Hospital of Shantou University Medical College; Tumor Hospital of Shantou University Medical College, Eastern, Northern, and Western Guangdong's talent development aiding program
Cervical Cancer
 
 
2018-004720-11: Phase 3 Study of Pembrolizumab with Maintenance Olaparib or Maintenance Pemetrexed in 1L Metastatic Nonsquamous NSCLC

Ongoing
3
792
Europe, RoW
KEYTRUDA® (pembrolizumab, MK-3475), Pembrolizumab, Olaparib, ALIMTA, Pemetrexed, MK-3475, MK-7339, Solution for infusion, Film-coated tablet, Powder for concentrate for solution for infusion, KEYTRUDA® (pembrolizumab, MK-3475), ALIMTA
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,, Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co.,
Stage IV lung cancer condition, Stage IV lung cancer condition, Diseases [C] - Cancer [C04]
 
 
NCT00392327: Chemotherapy and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Previously Untreated, High-Risk Medulloblastoma/PNET

Active, not recruiting
3
379
Europe, Canada, US, RoW
Carboplatin, Blastocarb, Carboplat, Carboplatin Hexal, Carboplatino, Carboplatinum, Carbosin, Carbosol, Carbotec, CBDCA, Displata, Ercar, JM-8, JM8, Nealorin, Novoplatinum, Paraplatin, Paraplatin AQ, Paraplatine, Platinwas, Ribocarbo, Cisplatin, Abiplatin, Blastolem, Briplatin, CDDP, Cis-diammine-dichloroplatinum, Cis-diamminedichloridoplatinum, Cis-diamminedichloro Platinum (II), Cis-diamminedichloroplatinum, Cis-dichloroammine Platinum (II), Cis-platinous Diamine Dichloride, Cis-platinum, Cis-platinum II, Cis-platinum II Diamine Dichloride, Cismaplat, Cisplatina, Cisplatinum, Cisplatyl, Citoplatino, Citosin, Cysplatyna, DDP, Lederplatin, Metaplatin, Neoplatin, Peyrone's Chloride, Peyrone's Salt, Placis, Plastistil, Platamine, Platiblastin, Platiblastin-S, Platinex, Platinol, Platinol- AQ, Platinol-AQ, Platinol-AQ VHA Plus, Platinoxan, Platinum, Platinum Diamminodichloride, Platiran, Platistin, Platosin, Cyclophosphamide, (-)-Cyclophosphamide, 2H-1,3,2-Oxazaphosphorine, 2-[bis(2-chloroethyl)amino]tetrahydro-, 2-oxide, monohydrate, Asta B 518, B-518, Carloxan, Ciclofosfamida, Ciclofosfamide, Cicloxal, Clafen, Claphene, CP monohydrate, CTX, CYCLO-cell, Cycloblastin, Cycloblastine, Cyclophospham, Cyclophosphamid monohydrate, Cyclophosphamide Monohydrate, Cyclophosphamidum, Cyclophosphan, Cyclophosphane, Cyclophosphanum, Cyclostin, Cyclostine, Cytophosphan, Cytophosphane, Cytoxan, Fosfaseron, Genoxal, Genuxal, Ledoxina, Mitoxan, Neosar, Revimmune, Syklofosfamid, WR- 138719, WR-138719, Filgrastim, Filgrastim Biosimilar Filgrastim-sndz, Filgrastim Biosimilar Tbo-filgrastim, Filgrastim XM02, Filgrastim-aafi, Filgrastim-ayow, Filgrastim-sndz, G-CSF, Granix, Neupogen, Neutroval, Nivestym, r-metHuG-CSF, Recombinant Methionyl Human Granulocyte Colony Stimulating Factor, Releuko, rG-CSF, Tbo-filgrastim, Tevagrastim, XM02, Zarxio, Isotretinoin, 13-cis retinoic acid, 13-cis-Retinoate, 13-cis-Retinoic Acid, 13-cis-Vitamin A Acid, 13-cRA, Absorica, Accure, Accutane, Amnesteem, cis-Retinoic Acid, Cistane, Claravis, Isotretinoinum, Isotrex, Isotrexin, Myorisan, Neovitamin A, Neovitamin A Acid, Oratane, Retinoicacid-13-cis, Ro 4-3780, Ro-4-3780, Roaccutan, Roaccutane, Roacutan, Sotret, ZENATANE, Laboratory Biomarker Analysis, Quality-of-Life Assessment, Quality of Life Assessment, Radiation Therapy, Cancer Radiotherapy, Energy Type, ENERGY_TYPE, Irradiate, Irradiated, Irradiation, Radiation, Radiation Therapy, NOS, Radiotherapeutics, Radiotherapy, RT, Therapy, Radiation, Vincristine Sulfate, Kyocristine, Leurocristine Sulfate, Leurocristine, sulfate, Oncovin, Vincasar, Vincosid, Vincrex, Vincristine, sulfate
Children's Oncology Group, National Cancer Institute (NCI)
Anaplastic Medulloblastoma, Medulloblastoma
06/19
01/25
2019-001077-87: Patient reported outcomes in term of swallowing and quality of life after prophylactic versus reactive percutaneous endoscopic gastrostomy tube placement in advanced oropharyngeal cancer patients treated with definitive chemo-radiotherapy

Not yet recruiting
3
121
Europe
Cisplatin, Concentrate for solution for injection
Institut Jules Bordet, Les amis de Bordet
advanced head and neck cancer, advanced head and neck cancer, Diseases [C] - Cancer [C04]
 
 
2016-001784-36: Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours

Ongoing
3
360
Europe
Concentrate for solution for infusion
Rheinische Friedrich-Wilhelms-Universität Bonn, Deutsche Krebshilfe
Extracranial germ cell tumours of any malignant histology, primary site and stage, Patients with extracranial malignant germ cell tumours., Diseases [C] - Cancer [C04]
 
 
CheckMate 9LA, NCT03215706 / 2017-001195-35: A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC

Checkmark Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Sep 2022 - Sep 2022: Exploratory analysis from CheckMate 9LA trial in combination with Yervoy in mNSCLC at ESMO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Opdivo for NSCLC at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from CheckMate 9LA trial in combination with Opdivo for NSCLC at ASCO 2022
Checkmark Presentation of data from CheckMate 9LA trial in combination with Yervoy for NSCLC at ASCO 2022
More
Active, not recruiting
3
719
Europe, Canada, Japan, US, RoW
Ipilimumab, Yervoy, BMS734016, Nivolumab, Opdivo, BMS936558, Carboplatin, Paclitaxel, Taxol, Pemetrexed, Alimta, Cisplatin, Platinol
Bristol-Myers Squibb
Non-Small Cell Lung Cancer
08/19
01/26
NCT01880359: AF CRT +/- Nimorazole in HNSCC

Active, not recruiting
3
640
Europe, RoW
Cisplatin, Radiotherapy, Placebo, Nimorazole
European Organisation for Research and Treatment of Cancer - EORTC, Danish Head and Neck Cancer Group
Locally Advanced Head and Neck HPV Negative Squamous Cell Cancers
09/19
01/23
2019-001478-27: Prophylactic surgery plus hyperthermic intraperitoneal chemotherapy (HIPEC CO2) versus standard surgery in gastric carcinoma at high risk of peritoneal carcinomatosis. Chirurgia profilattica e chemioterapia ipertermica intraperitoneale (HIPEC CO2) verso chirurgia standard in pazienti affetti da tumore gastrico ad alto rischio di sviluppare carcinosi peritoneale.

Not yet recruiting
3
240
Europe
MITOMICINA, Cisplatin, [L01DC03], [L01XA01], Powder and solvent for solution for injection
Associazione Chirurghi Ospedalieri Italiani, ACTA group
Patients with gastric carcinoma at high risk of developing peritoneal carcinomatosis, suitable to radical surgery. Pazienti con tumore gastrico ad alto rischio di carcinomatosi peritoneale candidabili a chirurgia radicale., Patients with gastric carcinoma at high risk of developing peritoneal carcinomatosis, suitable to radical surgery. Pazienti con tumore gastrico ad alto rischio di carcinomatosi peritoneale candidabili a chirurgia radicale., Diseases [C] - Cancer [C04]
 
 
2018-004250-17: International Trial for Patients with High Risk Medulloblastoma

Ongoing
3
850
Europe
Thiotepa, Vincristine, Lomustine, Cyclophosphamide, Temozolomide, Carboplatin, Cisplatin, [Thiotepa], [VIncristina solfato], [Lomustine], [Ciclofosfamide], [Temozolomide], [Carboplatino], [Cisplatino], Powder for concentrate for solution for infusion, Solution for injection/infusion, Capsule, hard, Powder for solution for injection/infusion, Concentrate for solution for infusion, TEPADINA, Vincristine Sulphate 1 mg/ml Injection, Lomustine "medac", Cyclophosphamide, Temodal®, Carboplatin, Cisplatin
University of Birmingham, UNIVERSITY OF BIRMINGHAM, Cancer Research UK, , Barncancerfonden
Histologically proven high-risk medulloblastoma, with any of the currently defined histological subtypes. High-risk disease is defined as patients with sonic hedgehog (SHH) subgroup or non-SHH/non-wingless-type (WNT) (Groups 3 and 4) medulloblastoma, with at least one additional high risk feature, Brain tumour, Diseases [C] - Cancer [C04]
 
 
2019-002784-10: Study in patients with untreated extensive-stage small cell lung cancer with carboplatin or cisplatin plus etoposide with Atezolizumab Estudio para pacientes con cáncer de pulmón microcítico en etapa avanzada no tratado con carboplatino o cisplatino más etopósido con Atezolizumab

Ongoing
3
150
Europe
Atezolizumab, RO5541267/F03, Concentrate for solution for infusion, Tecentriq.
Roche Farma S.A. (Soc. Unipersonal), Roche Farma S.A. (Soc. Unipersonal)
First-line treatment for extensive-stage small cell lung cancer Primera línea de tratamiento en pacientes con Cáncer de pulmón microcítico en etapa avanzada, Untreated extensive-stage small cell lung cancer Cáncer de pulmón de célula pequeña en etapa avanzada no tratado, Diseases [C] - Cancer [C04]
 
 
MICHELE, NCT06156514: Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

Recruiting
3
140
RoW
Gemcitabine, Cisplatin
National Institute of Cancerología
Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy
11/26
12/29
2018-001415-75: Induction chemotherapy followed by standard therapy in cervical cancer with aortic lymph node involvement Chimiothérapie d'induction suivie du traitement standard dans les cancers du col de l'utérus avec envahissement ganglionnaire aortique

Not yet recruiting
3
310
Europe
Solution for infusion, Concentrate for solution for infusion, CARBOPLATINE, PACLITAXEL, CISPLATINE
CHU de TOULOUSE, DGOS PHRC 2016
Cervical cancer with positive para-aortic lymph nodes Cancer du col de l'utérus avec envahissement ganglionnaire aortique, Cervical cancer Cancer du col de l'utérus, Diseases [C] - Cancer [C04]
 
 
NCT02363400: A Phase III Trial in NPC With Post-radiation Detectable Plasma EBV DNA

Enrolling by invitation
3
147
RoW
MEP, epirubicin, cisplatin, oral Tegafur-uracil, mitomycin-C
National Health Research Institutes, Taiwan, National Taiwan University Hospital, Mackay Memorial Hospital, China Medical University Hospital, National Cheng-Kung University Hospital, Kaohsiung Veterans General Hospital., Taichung Veterans General Hospital
Nasopharyngeal Carcinoma
12/19
12/22
ChiCTR-IIR-17011559: Randomized clinical study of paclitaxel combined with lobaplatin compared to paclitaxel combine with cisplatin in neoadjuvant chemotherapy and sequential concurrent chemoradiotherapy of locally advanced cervical cancer

Recruiting
3
200
 
Paclitaxel + lobaplatin ;Paclitaxel +cisplatin
Guizhou Cancer Hospital; Guizhou Cancer Hospital, Self-Raised
Cervical Cancer
 
 
DANUBE , NCT02516241 / 2015-001633-24: Study of MEDI4736 (Durvalumab) With or Without Tremelimumab Versus Standard of Care Chemotherapy in Urothelial Cancer

Checkmark From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Sep 2020 - Sep 2020: From DANUBE trial as monotherapy or in combination with tremelimumab vs chemo in Stage IV urothelial cancer
Checkmark From DANUBE trial in combination with durvalumab vs chemo in Stage IV urothelial cancer
Sep 2020 - Sep 2020: From DANUBE trial in combination with durvalumab vs chemo in Stage IV urothelial cancer
Hourglass Mar 2020 - Jun 2020 : Regulatory submission in EU (based on DANUBE trial) for 1L bladder cancer in combination with tremelimumab
More
Active, not recruiting
3
1126
Europe, Canada, Japan, US, RoW
MEDI4736 (Durvalumab), Tremelimumab, Cisplatin, Carboplatin, Gemcitabine
AstraZeneca
Urothelial Cancer
01/20
12/24
CASPIAN, NCT03043872 / 2016-001203-23: Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer

Checkmark From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Sep 2021 - Sep 2021: From CASPIAN trial for extensive-stage SCLC at ESMO 2021
Checkmark From CASPIAN trial in 1L SCLC at ESMO 2020
Sep 2020 - Sep 2020: From CASPIAN trial in 1L SCLC at ESMO 2020
Checkmark From CASPIAN trial in combination with tremelimumab for 1L extensive-stage SCLC at ASCO 2020
More
Active, not recruiting
3
987
Europe, Japan, US, RoW
Durvalumab, Tremelimumab, Carboplatin, Cisplatin, Etoposide
AstraZeneca
Small Cell Lung Carcinoma Extensive Disease
01/20
12/24
NCT01561586: Tri-weekly Cisplatin Based Chemoradiation in Locally Advanced Cervical Cancer

Recruiting
3
374
RoW
Weekly cisplatin with RT, Cisplatin, Tri-weekly cisplatin with RT
Korea Cancer Center Hospital, Seoul National University Hospital, Asan Medical Center, Gangnam Severance Hospital
Cervical Cancer
03/20
03/23
2019-000944-82: Pembrolizumab or Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable BTC

Not yet recruiting
3
1048
Europe
pembrolizumab, Keytruda (pembrolizumab, MK-3475), MK-3475, Solution for infusion, Keytruda (pembrolizumab, MK-3475)
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC, MERCK SHARP & DOHME CORP. UNA SUSSIDIARIA DI MERCK & CO. INC., Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Merck Sharp & Dohme LLC
Advanced and/or Unresectable Biliary Tract Carcinoma (Intrahepatic, Extrahepatic, or Gallbladder), Advanced (metastatic) and/or unresectable (locally advanced) biliary tract cancer (intra-or extrahepatic cholangiocarcinoma or gallbladder cancer). This study is for treatment naïve participants, Diseases [C] - Cancer [C04]
 
 
CheckMate 743, NCT02899299 / 2016-001859-43: Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma Patients

Checkmark Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Sep 2022 - Sep 2022: Four-year update and biomarker analyses CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2022
Checkmark Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
Sep 2021 - Sep 2021: Presenation of data from CheckMate743 trial in combination with Opdivo for 1L malignant pleural mesothelioma at ESMO 2021
Checkmark Presenation of data from CheckMate743 trial in combination with Yervoy for 1L malignant pleural mesothelioma at ESMO 2021
More
Completed
3
605
Europe, Japan, US, RoW
Nivolumab, BMS-936558, Opdivo, Ipilimumab, BMS-734016, Yervoy, Pemetrexed, Cisplatin, Carboplatin
Bristol-Myers Squibb, Ono Pharmaceutical Co. Ltd
Mesothelioma
03/20
04/23
Orient-12, NCT03629925: Sintilimab in Combination With Gemcitabine and Platinum-Based Chemotherapy as First-Line Therapy for Advanced or Metastatic Squamous NSCLC

Checkmark NMPA approved sNDA in combination with gemcitabine for locally advanced or metastatic sqNSCLC
Jun 2021 - Jun 2021: NMPA approved sNDA in combination with gemcitabine for locally advanced or metastatic sqNSCLC
Checkmark Data from orient-12 trial for advanced or recurrent squamous NSCLC at ESMO 2020
Sep 2020 - Sep 2020: Data from orient-12 trial for advanced or recurrent squamous NSCLC at ESMO 2020
Checkmark Data from trial for 1L squamous NSCLC
More
Completed
3
357
RoW
Sintilimab, IBI308, Gemcitabine, Cisplatin, Placebo, Carboplatin
Innovent Biologics (Suzhou) Co. Ltd.
Squamous NSCLC
03/20
09/21
2020-000149-15: Combined chemotherapy and radiotherapy followed by planned surgery compared to combined chemotherapy and radiotherapy with surgery only when really needed, for patients with cancer in the esophagus.

Not yet recruiting
3
1020
Europe
Carboplatin, Paklitaxel, Cisplatin, 5-fluorouracil, Oxaliplatin, Calcium folinate, Concentrate for solution for infusion, Concentrate and solvent for solution for infusion, Solution for injection/infusion
Karolinska University Hospital, Karolinska University Hospital, Swedish Research Council
Resectable locally advanced squamous cell carcinoma (SCC) of the esophagus, Cancer in the gullet (esophagus), which is possible to operate., Diseases [C] - Cancer [C04]
 
 
TROG 12.01, NCT01855451 / ACTRN12613000279729: Weekly Cetuximab/RT Versus Weekly Cisplatin/RT in HPV-Associated Oropharyngeal Squamous Cell Carcinoma

Active, not recruiting
3
189
RoW
Cetuximab, RT (70 Gy in 35 fractions), Cisplatin
Trans Tasman Radiation Oncology Group, National Health and Medical Research Council (NHMRC), Merck Serono Australia
HPV Positive Oropharyngeal Squamous Cell Carcinoma
04/20
08/23
 

Download Options